Sertraline

Zoloft

Les sections ci-dessous sont citées de la notice en anglais, car c'est ce document qui porte l'autorisation. Lorsqu'une autorité européenne publie les mêmes informations en français, le lien figure dans les sources. Nous ne traduisons pas nous-mêmes les textes réglementaires : une erreur de traduction dans une contre-indication serait plus dangereuse qu'une ligne en langue étrangère.

01Usages autorisés

• Major depressive disorder (MDD)
• Obsessive-compulsive disorder (OCD)
• Panic disorder (PD)
• Posttraumatic stress disorder (PTSD)
• Social anxiety disorder (SAD)
• Premenstrual dysphoric disorder (PMDD)

02Formes et dosages

• Tablets: 25 mg, 50 mg and 100 mg
• Oral solution: 20 mg/mL

03Comment il se prend

• If inadequate response to starting dosage, titrate in 25-50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD
• See Full Prescribing Information for titration in PMDD
• Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage; Moderate or severe: Not recommended
• When discontinuing ZOLOFT, reduce dose gradually
• Oral solution: Must be diluted before administration

04Ne doit pas être utilisé en cas de

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs
• Concomitant use of pimozide
• Known hypersensitivity to sertraline or excipients
• ZOLOFT oral solution only: Concomitant use of disulfiram

05Interactions

• Protein-bound drugs: Monitor for adverse reactions and reduce dosage of ZOLOFT or other protein-bound drugs (e.g., warfarin) as warranted.
• CYP2D6 substrates: Reduce dosage of drugs metabolized by CYP2D6.

06Mises en garde et précautions

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue ZOLOFT and serotonergic agents and initiate supportive treatment.
• Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk.
• Activation of Mania/Hypomania: Screen patients for bipolar disorder.
• Seizures: Use with caution in patients with seizure disorders.
• Angle Closure Glaucoma: Avoid use of antidepressants, including ZOLOFT, in patients with untreated anatomically narrow angles.
• QTc Prolongation: ZOLOFT should be used with caution in patients with risk factors for QTc prolongation.
• Sexual Dysfunction: ZOLOFT may cause symptoms of sexual dysfunction.

07Effets indésirables fréquents

• Most common adverse reactions (≥5% and twice placebo) in all pooled placebo-controlled clinical trials of all ZOLOFT-treated patients with MDD, OCD, PD, PTSD, SAD and PMDD were nausea, diarrhea/loose stool, tremor, dyspepsia, decreased appetite, hyperhidrosis, ejaculation failure, and decreased libido (see Table 3).
• Most common adverse reactions in trials of ZOLOFT (≥5% and twice placebo) by indication that were not mentioned previously.
• Most common adverse reactions (>2% and twice placebo) included: ejaculation failure, decreased libido, erectile dysfunction, ejaculation disorder, and male sexual dysfunction.

08Grossesse

Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage. Overall, available published epidemiologic studies of pregnant women exposed to sertraline in the first trimester suggest no difference in major birth defect risk compared to the background rate for major birth defects in comparator populations.

09Mécanisme d'action

Sertraline potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT).

Cette section rapporte les informations produit approuvées. Le texte est condensé à partir du résumé de l'autorité elle-même, et le document complet figure dans les sources.